You just read:

Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection

News provided by

Gilead Sciences, Inc.

Aug 17, 2017, 05:59 ET